8-K: Milestone Pharma Reports Q4/FY25 Results, CARDAMYST Launch

Milestone Pharmaceuticals announced its Q4 and full-year 2025 financial results, highlighting the successful commercial launch of CARDAMYST nasal spray for PSVT and a strong cash position.

Summary

• The U.S. Food and Drug Administration (FDA) approved CARDAMYST (etripamil) nasal spray on December 12, 2025, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
• CARDAMYST became broadly available through retail pharmacies in the United States in late January 2026.
• A national sales force, consisting of approximately 60 sales representatives, was fully deployed in mid-February, engaging primarily with cardiologists, electrophysiologists, and advanced practice providers.
• Initial prescription fills support underlying demand and the effectiveness of investments in reimbursement support.
• The Marketing Authorization Application (MAA) for etripamil nasal spray in PSVT was accepted by the European Medicines Agency (EMA), with a decision on approval expected by the first half of 2027.
• The company plans a Phase 3 registrational program for etripamil as a potential treatment for patients with Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR).
• Cash, cash equivalents, and short-term investments were $106.0 million as of December 31, 2025, compared to $69.7 million on December 31, 2024.
• Pro forma cash, including $94 million from subsequent financing activities, totals $200 million, supporting an operating runway into late 2027.
• Revenue for the full year ended December 31, 2025, was $1.5 million, resulting from a milestone payment for CARDAMYST NDA approval.
• Net loss for the fourth quarter of 2025 was $17.4 million, or $0.16 per share, compared to $12.4 million, or $0.19 per share, for the prior year period.
• Net loss for the full year ended December 31, 2025, was $63.1 million, or $0.75 per share, compared to $41.5 million, or $0.67 per share, for the prior year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by the successful commercial launch of CARDAMYST, robust initial market engagement, and a significantly strengthened cash position that extends the operating runway. While losses increased, this is attributable to strategic launch investments.

Positives

• FDA approval of CARDAMYST (etripamil) nasal spray on December 12, 2025, represents the first new treatment option in 30 years for over two million patients with PSVT.
• The commercial launch of CARDAMYST is on track, with initial engagement from healthcare providers and payers tracking or exceeding pre-launch expectations.
• Clinical studies demonstrated that participants using CARDAMYST were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo.
• A strong pro forma cash position of $200 million (including $106 million at year-end 2025 and $94 million from subsequent financing activities) supports a robust launch and operating runway into late 2027.
• Milestone received a $75 million payment from RTW Royalty I DAC on January 12, 2026, in connection with the FDA approval of CARDAMYST.
• The company raised $19 million in net proceeds from ATM sales and Series A Warrant exercises.
• The Marketing Authorization Application (MAA) for etripamil nasal spray in PSVT was accepted by the European Medicines Agency (EMA), with a decision expected by the first half of 2027.
• A poster presentation at the American College of Cardiology (ACC) Scientific Session on March 30, 2026, will highlight minimal blood pressure effects of CARDAMYST, supporting its potential for safe, self-administration.

Negatives

• Net loss for the full year 2025 increased to $63.1 million ($0.75 per share) from $41.5 million ($0.67 per share) in 2024.
• Research and development expense for the full year 2025 increased to $18.1 million from $14.4 million in 2024.
• Commercial expense for the full year 2025 significantly increased to $28.3 million from $11.0 million in 2024, primarily due to preparations for the CARDAMYST launch.

Risks

• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of clinical trials.
• Risks and uncertainty related to the complexity inherent in cleaning, verifying, and analyzing trial data.
• Whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine, ongoing disputes in the Middle East, and overall fluctuations in financial markets.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of capital resources and the ability to raise additional capital in the current economic climate.
• Whether future interactions with the EMA will have satisfactory outcomes.
• Whether and when, if at all, the Marketing Authorization Application (MAA) for etripamil will be approved by the EMA.

Future Outlook

Milestone Pharmaceuticals expects to report figures on prescriptions and prescribers for CARDAMYST in future quarterly announcements as a critical mass of data accumulates. The company anticipates a European decision on approval for etripamil (TACHYMIST) by the first half of 2027 and plans to initiate a Phase 3 registrational program for etripamil in AFib-RVR, leveraging the sNDA regulatory pathway.

Management Comments

• "We are excited to see that our commercial launch of CARDAMYST and the initial engagement with providers, patients and payers is tracking or exceeding our pre-launch expectations." Joseph Oliveto, President and Chief Executive Officer.
• "Feedback from prescribers supports our belief that there is meaningful demand for a convenient, self-administered option to treat episodes of PSVT, and patient reactions to having CARDAMYST in hand is inspiring." Joseph Oliveto, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that the FDA approval of CARDAMYST marks a significant milestone in the cardiovascular treatment landscape, introducing the first new self-administered option for PSVT in 30 years. This positions Milestone Pharmaceuticals to capture a substantial market share in a condition affecting over two million Americans, potentially disrupting traditional emergency department-centric treatment paradigms. The planned Phase 3 program for AFib-RVR also indicates a strategic expansion into a broader arrhythmia market, aligning with the growing demand for convenient, patient-centric cardiac care solutions.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to FDA approval, successful product launch, strengthened cash position, and potential for future revenue growth.
• Patients (PSVT): Significant positive impact by providing the first self-administered, rapid-acting treatment option in 30 years, potentially reducing emergency department visits and improving quality of life.
• Healthcare Providers (Cardiologists, Electrophysiologists, APPs): Provides a new, convenient treatment option for PSVT patients, enhancing their ability to manage the condition.
• Employees: Positive impact from the company's growth and commercialization efforts, including the deployment of a national sales force.

Next Steps

• Future quarterly announcements are expected to report figures on CARDAMYST prescriptions and prescribers.
• Presentation of CARDAMYST at the American College of Cardiology (ACC) Annual Scientific Session on March 30, 2026, in New Orleans.
• The ACC Scientific Session will serve as a major launch event for the cardiology community.
• European Medicines Agency (EMA) decision on approval for etripamil (TACHYMIST) expected by the first half of 2027.
• Planned Phase 3 registrational program for etripamil in AFib-RVR.
• Refer to the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 20, 2026, for further financial details.

Key Dates

Recommendation

The FDA approval and successful initial commercial launch of CARDAMYST, a first-in-30-years treatment for a significant patient population, represent a transformative event for Milestone Pharmaceuticals. The strong pro forma cash position extending the operating runway into late 2027, coupled with positive early market engagement and expansion plans into AFib-RVR, indicates robust growth potential. While increased expenses led to a higher net loss, these are strategic investments for a product with substantial market opportunity. The EMA acceptance further de-risks international expansion. This filing suggests a company poised for significant value creation.

Keywords

CARDAMYST, etripamil, PSVT, Milestone Pharmaceuticals, FDA approval, biopharmaceutical, cardiovascular medicine, AFib-RVR, nasal spray, Q4 2025 results, commercial launch, pharmaceuticals, biotech